



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

08/790540

dk

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
--------------------	-------------	-----------------------	------------------

08/790,540 01/30/97 HUSE

W P-IX-2405

EXAMINER

HM22/1207

DAVID A GAY  
CAMPBELL & FLORES  
SUITE 700  
4370 LA JOLLA VILLAGE DRIVE  
SAN DIEGO CA 92122

CAMPBELL, F	PAPER NUMBER
-------------	--------------

1644

20

DATE MAILED:

12/07/99

This is a communication from the examiner in charge of your application.  
COMMISSIONER OF PATENTS AND TRADEMARKS

OFFICE ACTION SUMMARY

☒ Responsive to communication(s) filed on 9/23/99

☒ This action is FINAL.

☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 D.C. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

- ☒ Claim(s) 1-31 is/are pending in the application.  
Of the above, claim(s) 22 19-25 is/are withdrawn from consideration.
- ☐ Claim(s) is/are allowed.
- ☒ Claim(s) 1-18, 26-31 is/are rejected.
- ☐ Claim(s) is/are objected to.
- ☐ Claim(s) are subject to restriction or election requirement.

Application Papers

- ☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.
- ☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.
- ☐ The proposed drawing correction, filed on \_\_\_\_\_ is ☐ approved ☐ disapproved.
- ☐ The specification is objected to by the Examiner.
- ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- ☐ All ☐ Some\* ☐ None of the CERTIFIED copies of the priority documents have been
- ☐ received.
- ☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_
- ☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

- ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- ☐ Notice of Reference Cited, PTO-892
- ☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_
- ☐ Interview Summary, PTO-413
- ☐ Notice of Draftsperson's Patent Drawing Review, PTO-948
- ☐ Notice of Informal Patent Application, PTO-152

--SEE OFFICE ACTION ON THE FOLLOWING PAGES--

NOT AVAILABLE COPY

### DETAILED ACTION

1. The request filed on for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 08/790,540 is acceptable and a CPA has been established.

An Office Action on the CPA follows.

It is noted that applicant's Request Transmittal, filed 12/8/00 (Paper No. 28), requests entry of the unentered amendment filed 6/12/00 (Paper No. 24).

However, applicant's amendment, filed 6/12/00 (Paper No. 24), was entered, as indicated in the Advisory Action (Paper No. 25), mailed 8/14/00.

Claims 1-18 and 26-31 are under consideration in the instant application.

Claims 19-25 have been withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a nonelected invention.

2. The text of those sections of Title 35 USC not included in this Action can be found in a prior Action. The rejections of record can be found in previous Office Actions (Paper Nos. 5/8/13/16/20/25).

Given the absence of additional rebuttal to the outstanding rejections of record in applicant's amendment, filed 12/8/00 (Paper No. 28); the rejections are maintained for the reasons of record.

3. Formal drawings have been submitted which comply with 37 CFR 1.84.

4. Claims 1, 2, 9, 10, 12-18 are rejected under 35 U.S.C. § 112, first paragraph, as the specification does not contain a written description of the claimed invention, in that the disclosure does not reasonably convey to one skilled in the relevant art that the inventor(s) had possession of the claimed invention at the time the application was filed. The specification as originally filed does not provide support for the invention as now claimed: "having greater than 88%/79% identity".

Applicant's arguments, filed 6/12/00 (Paper No. 24), were fully considered and not found convincing for the reasons of record set forth in Paper Nos. 20/25.

Applicant's amendment, filed 9/23/99 (Paper No. 19), directed support to page 45 for these above-mentioned "limitations" and applicant's arguments, filed 6/12/00 (Paper No. 24), refers to various other passages in the specification as-filed.

As pointed out previously, while the specification as filed provides for 'CL had "88/79%" identity to frameworks 1, 2 and 3 of LM609 heavy chain/light chain; there is insufficient written description for "greater than" as well as "at least one LM609 CDR-grafted heavy/light chain polypeptide comprising a variable region amino acid sequence greater than 88%/79% identity with that shown in Figure 1A/1B" or "functional fragments" thereof, or "nucleic acids" encoding the same; as currently recited..

The specification as filed does not provide sufficient written description for these newly claimed limitations", as they are currently recited. Applicant's reliance on generic disclosure and possibly a single species does not provide sufficient direction and guidance to the "currently claimed limitations". It cannot be said that a subgenus is necessarily described by a genus encompassing it and a species upon which it. Also, see MPEP 2163.05 Changes to the Scope of Claims. The instant claims now recite limitations which were not clearly disclosed in the specification as-filed, and now change the scope of the instant disclosure as-filed. Such limitations recited in the present claims, which did not appear in the specification, as filed, introduce new concepts and violate the description requirement of the first paragraph of 35 U.S.C. 112.

Applicant is required to cancel the new matter in the response to this Office action

Alternatively, applicant is invited to provide sufficient written support for the "limitations" indicated above.

5. Claims 1-18, 26-31 stand rejected under 35 U.S.C. § 102(f) because the applicants did not invent the claimed subject matter.

As pointed out previously; applicant's arguments, in conjunction with the Huse declaration, filed 12/14/98 (Paper No. 12), have been as well as U.S. Patent No. 5,753,230 (1449) and Biotechnology Newswatch Biotechnology Newswatch (1/16/95) presented an ambiguity with regard to the inventorship of the claimed invention.

Applicant's amendments in conjunction with the Huse and Glaser declarations under 37 C.F.R. § 1.132, filed 9/24/99 and 6/12/00 (Paper Nos. 19/23/24), have been fully considered but are not found convincing essentially for the reasons of record.

Applicant maintains that the inventorship has been reviewed and determined to be correct and that both Huse and Glaser have been determined to be inventors of the claimed compositions.

As pointed out previously; it was noted that the Huse Declaration, filed 12/14/98 (Paper No. 12) indicates that he conceived the idea of humanizing  $\alpha_v\beta_3$  inhibitory antibodies.

It is noted that the Huse/Glaser Declaration under 37 C.F.R. § 1.132, filed 6/12/00 (Paper No. 23), states that both Huse and Glaser are joint inventors of the instant claims

Applicant maintains that Cheresh and Brooks could be considered, at most, technical collaborator but not an inventor of the claimed antibodies and nucleic acids referenced as specifically recited SEQ ID NOS.

However, applicant has not provided sufficient objective evidence or information to address either the contribution of Glaser to the claimed invention, given the first Huse Declaration, filed 12/14/98 (Paper No. 12), which indicated that he alone conceived the idea of humanizing  $\alpha_v\beta_3$  inhibitory antibodies or the contribution of Cheresh as a scientific collaborator, but not as an inventor.

Again, as pointed out previously, applicant has not provided the facts concerning the nature and role of Cheresh as a collaborator, with respect to humanizing the LM609 antibody. It is noted that Biotechnology Newswatch acknowledges that Cheresh was the principal investigator. It is clear that Cheresh developed the LM609 antibody and that it was possible to determine without undue experimentation antibodies and humanized antibodies having the same properties (see U.S. Patent No. 5,753,230, particularly columns 15-19). Further, U.S. Patent No. 5,753,230 claims the use of LM609 antibody as well as humanized versions thereof. Similarly the instant specification acknowledges that Cheresh developed the LM609 antibody (see page 9, for example) and that generating humanized/CDR-grafted antibodies were known in the art at the time the invention was made (see page 17, for example). Again, it is clear that given U.S. Patent No. 5,753,230 that humanizing  $\alpha_v\beta_3$  inhibitory antibodies, including the LM609 antibody was known in the prior art by others. Again, it is noted that Brooks was an inventor on U.S. Patent No. 5,753,230.

Also, it is noted that Huse and Glaser are listed as inventors of the pending claims of copending USSN 08/791,391.

As pointed out previously, the arguments of counsel cannot take the place of evidence in the record. In re Schulze 346 F.2d 600, 502; 145 USPQ 716, 718 (CCPA 1965). See MPEP 716.01© for examples of attorney statements which are not evidence and which must be supported by an appropriate affidavit or declaration.

To resolve the ambiguity, applicants may file declarations by the non-applicant(s) Cheresh (and Brooks) disclaiming the invention or a declaration by applicant setting forth the facts which provide an explanation as to why the non-applicant are not inventors. Further, applicant may provide facts why Glaser is an inventor.

Applicant's arguments are not found persuasive.

6. Claim 26 stands rejected under 35 U.S.C. § 102(e) as being anticipated by Brooks et al. (U.S. Patent No. 5,753,230) essentially for the reasons of record set forth in Paper Nos. 16/20/25.

Applicant's arguments in conjunction with the Huse declaration under 37 C.F.R. § 1.132, filed 9/23/99 and 6/12/00 (Paper Nos. 19/24), have been fully considered but are not found convincing essentially for the reasons of record.

Given that claim 26 recites "of a modification thereof or a functional fragments of said LM609 CDR-grafted antibody" and the prior art teaching of humanized LM609 antibodies; applicant's arguments concerning the particular structural characteristics of the claimed limitations are not found persuasive. Applicant is reminded that no more of the reference is required than that it sets forth the substance of the invention. The claimed "limitations" read on "modifications thereof or a functional fragments of said LM609 CDR-grafted antibody"

Applicant's arguments relying upon the particular SEQ ID NOS: recited in claim 26 do not obviate the prior art teaching, as it reads on "a modification thereof or a functional fragments of said LM609 CDR-grafted antibody" of the same LM609 antibody of the claimed invention.

Applicant's arguments are not found persuasive.

7. Claims 1-18 and 26-31 stand rejected under 35 U.S.C. § 103 as being unpatentable over Brooks et al. (U.S. Patent No. 5,753,230; 1449) in view of art known gene cloning and expression strategies for deriving recombinant antibodies and fragments thereof, as disclosed on pages 3-37 or Examples I and II of the instant specification or as cited by references on the 1449 for the reasons of record set forth in Paper Nos. 16/20/25.

The teachings of Brooks et al. in view of art known gene cloning and expression strategies for deriving recombinant antibodies and fragments thereof, as disclosed on pages 10-39 or Examples I and II of the instant specification or as cited by references on the 1449 are of record. Briefly, teach the LM609 antibody as well as humanized forms of this antibody and claim methods of using the LM609 antibody as well as humanized forms of this antibody (see entire document, particularly columns 15-19 and the claims). With respect to specific amino acid changes including those which are "modifications" would be obvious given the teachings of humanized LM609 antibodies and art known methods to generate such humanized antibodies which retain the desired functional characteristics of the native antibody and to alter said antibody for therapeutic uses, including human therapy, as taught and known in the prior art.

Applicant's arguments in conjunction with the Huse/Glaser declarations under 37 C.F.R. § 1.132, filed 9/24/99 and 6/12/00 (Paper Nos. 19/22/24), have been fully considered but are not found convincing essentially for the reasons of record.

Applicant's arguments and the examiner's rebuttal are essentially the same as of record.

Applicant arguments have essentially focused on whether the prior art taught the particular structural features of the LM609 antibody, particularly the nucleic acid or amino acid sequences of the LM609 antibody.

Applicant has argued that the claims recite structural characteristics which are not taught or suggested in any of the cited references. Applicant has argued that Brooks et al. do not teach or suggest the claimed human acceptor framework sequences LM609 CDR's, encompassed by SEQ ID NOS: 2,3,32, including the amino acid at position 49. Applicant asserts that the change of amino acid to three other amino acids unexpectedly results in functional antibody having integrin  $\alpha v \beta 3$  binding activity.

Applicant has argued in conjunction with Deuel that the prior art, including Brooks et al. does not teach nor suggest the nucleic acids having the structural characteristics of the specifically recited SEQ ID NOS.

Applicant has argued that the prior art describes the mouse antibody and not applicant's claimed non-mouse antibodies having human acceptor framework sequences with LM609 CDR's

Applicant has argued that Padlan teaches away from the claimed invention.

Applicant has argued in conjunction with the Huse Declaration that there were difficulties in cloning authentic DNA sequences.

The following is provided for applicant's convenience.

As pointed out previously; the amino acid and nucleic acid sequences associated with the LM609 antibody including those of humanized LM609 antibodies would have been available to the ordinary artisan, given the availability of the LM609 antibody and hybridoma together with general immunoglobulin gene cloning and expression strategies. It would have been a matter of routine experimentation well within the ordinary skill level of art to generate chimeric or humanized LM609 antibodies, DNA encoding said antibodies. Given the highly conserved nature of immunoglobulin gene organization and structure and the availability of probes and PCR primers for immunoglobulin gene cloning, one of ordinary skill in the art could have isolated the functionally rearranged heavy and light chain variable regions from the LM609 hybridoma cell line and determined their sequences with a complete expectation of success. For example, the ordinary artisan does not need to determine the amino acid sequences of a rearranged V (variable) region before cloning. The claims do not differ unexpectedly or unobviously from what one of ordinary skill in the art would have expected to obtain given the known LM609 hybridoma thereof, the known heavy and light chain and the art known techniques regarding the production of chimeric antibodies, as acknowledged by the number of available art known procedures disclosed in the instant specification and cited on the Information Disclosure Statement. The claimed DNA sequences must encode a recombinant antibody comprising heavy and/or light chain variable regions of the LM609 antibody.

Immunoglobulin gene structure and organization were well understood in the art at the time the claimed invention was made and that strategies for cloning the DNAs encoding immunoglobulin variable regions were well established in the art at the time the claimed invention was made, as were methods for the production of DNA constructs encoding immunoglobulin variable regions. In addition, it was known at the time the invention was made that the benefits of producing recombinant antibodies to reduce the immunogenicity of therapeutic and diagnostic antibodies in human patients. From the teachings of the references, it was apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

As pointed out in the previous Office Actions, it was noted that the instant disclosure relied upon standard humanization procedures to derive the claimed antibody and nucleic acid compositions. Also, it was noted that Biotechnology Newswatch (1/16/95 and 2/6/95) references above support the routine nature of providing an antibody/hybridoma of interest to a commercial interest to develop humanized antibodies and the nucleic acids encoding said antibodies by routineers in the art at the time the invention was made.

In contrast to applicant's assertions and for the reasons of record and reiterated above; the claimed antibodies and nucleic acids do not differ unexpectedly or unobviously from what one of ordinary skill in the art would have expected given the availability of the LM609 antibody and hybridoma in the prior art as well as the art known techniques regarding the production of chimeric and humanized antibodies at the time the invention was made, as acknowledged by the number of available art known procedures disclosed in the instant specification and cited on the Information Disclosure Statement.

For example, page 15, paragraph 1 of the specification discloses that functional replacement of the CDRs was performed by recombinant methods known to those skilled in the art, commonly referred to as CDR grafting. Also, page 20, paragraph 1 of the specification discloses that identification of amino acids to be changed can be accomplished by those skilled in the art using current information available regarding the structure and function of antibodies as well available and current information encompassing methods for CDR grafting procedures. In addition, page 20, paragraph 2 of the specification discloses using the above described methods known within the art, any or all of the non-identical amino acids can be changed either alone or in combination with amino acids at different positions to incorporate the desired number of amino acid substitutions at each of the desired positions. Page 21, paragraph 1 discloses that the functional replacement of amino acids is beneficial when producing grafted antibodies having human framework sequences since it allows for the rapid identification of equivalent amino acid residues without the need for structural information or the laborious procedures necessary to assess and identify which amino acid residues should be considered for substitution in order to successfully transfer binding function from the donor. Also see (Singer et al., J. Immunol. 150: 2844-2857, 1993 and Padlan, Mol. Immunol 28: 489-498, 1991 of the Information Disclosure Statement; which provide for art known procedures and expectation of success in humanizing known antibodies of interest, including deriving the appropriate

changes to derive the desired reduction in reduced immunogenicity and in desired specificity. The claimed grafted antibodies and associated nucleic acids were predictable by the known and practiced means (e.g. computer modeling) at the time the invention was made. It is noted that Padlan discloses the same procedures using the same frameworks in procedures for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties as relied upon in applicant's claimed invention (see entire document).

Therefore, it appears that applicant has relied upon the same starting material as the prior art (LM609 antibody and hybridoma) and that applicant has relied upon the same recombinant means to derive the same antibodies and nucleic acids derived from humanizing the LM609 antibody taught and claimed by the prior art. It is clear that Brooks et al. teach antibodies that have the same or similar immunoreactive characteristics and compete for binding to the same preselected target molecule as the LM609 antibody (see columns 15-18, particularly column 17). In contrast to applicant's assertions; humanizing the LM609 antibody or modifying humanized LM609 antibody and its associated nucleic acids in achieving the claimed limitations was known and obvious, given the same starting materials, including the LM609 antibody/hybridoma and acceptor molecules and given the same recombinant means to achieve the same humanized antibodies as clearly taught and known in the prior art. As pointed out above, the modifications other than simple CDR-grafted LM609 antibody appear to be predictable or to be predicated on the same standard and known computer modeling in the prior art in humanizing antibodies of interest.

Also as pointed out above, for examination purposes under art; the recitation of "a modification thereof that does not change the encoded amino acid sequence" reads on modifications which do not change the encoded amino acid sequence due to the degeneracy of the genetic codes as well as those which result in only a conservative substitution of the encoded amino acid sequence. Such modifications would have resulted in humanized LM609-specific antibodies encompassed by the claimed invention.

Also, the claims recited functional fragments thereof and again; such limitations would have been obvious in view of the prior art teaching of generating humanized LM609-specific antibodies.

Applicant's arguments are not found persuasive.

8. The non-statutory double patenting rejection, whether of the obvious-type or non-obvious-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent. *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Van Ornam*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); and *In re Goodman*, 29 USPQ2d 2010 (Fed. Cir. 1993).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321 (b) and (c) may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.78 (d).

Effective January 1, 1994, a registered attorney or agent of record may sign a Terminal Disclaimer. A Terminal Disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

9. Claims 1-18, 26-31 stand provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-8, 15-26, 33-42 and 56-57 of copending application USSN 08/791,391 essentially for the reasons of record.

This is a *provisional* obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Applicant's previous amendment, filed 9/23/99 (Paper No. 19), request that this provisional ground of rejection be deferred until there is an indication of allowable subject matter

Applicant has provided for the common ownership of the instant application with USSN 08/791,391.

10. Claims 1-18, 26-31 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over  
claims 56-97 of copending USSN 09/016,061 and  
claims 1-20 and 25-33 of copending USSN 09/339,922.

Although the conflicting claims are not identical, they are not patentably distinct from each other because the pending claims appear to be drawn to similar or obvious variants of LM609-specific humanized antibodies, fragments and nucleic acids encoding said antibodies/fragments thereof.

It is acknowledged that certain LM609-specific modifications of USSN 09/016,061 and USSN 09/339,922 may be considered distinct species from the instant claims.

However, it is noted that SEQ ID NOS: 3,5,6 and 32 of USSN 09/016,061 and SEQ ID NOS: 3,4,5,6,31 and 32 of USSN 09/339,922 appear to read on the instant claims.

Applicant is invited to distinguish the pending claims from one another.

This is a *provisional* obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

11. Claims 1-18, 26-31 are directed to an invention not patentably distinct from  
claims 56-97 of copending USSN 09/016,061 and  
claims 1-20 and 25-33 of copending USSN 09/339,922.

Specifically, the conflicting claims are patentably distinct from each other because the pending claims are drawn similar or obvious variants of LM609-specific humanized antibodies, fragments and nucleic acids encoding said antibodies/fragments thereof

It is acknowledged that certain LM609-specific modifications of USSN 09/016,061 and USSN 09/339,922 may be considered distinct species from the instant claims.

However, it is noted that SEQ ID NOS: 3,5,6 and 32 of USSN 09/016,061 and SEQ ID NOS: 3,4,5,6,31 and 32 of USSN 09/339,922 appear to read on the instant claims.

Applicant is invited to distinguish the pending claims from one another.

Commonly assigned USSNs 09/016,061 and 09/339,922, discussed above, would form the basis for a rejection of the noted claims under 35 U.S.C. § 103 if the commonly assigned case qualifies as prior art under 35 U.S.C. § 102(f) or (g) and the conflicting inventions were not commonly owned at the time the invention in this application was made. In order for the examiner to resolve this issue, the assignee is required under 37 C.F.R. § 1.78(c) to either show that the conflicting inventions were commonly owned at the time the invention in this application was made or to name the prior inventor of the conflicting subject matter. Failure to comply with this requirement will result in a holding of abandonment of the application. A showing that the inventions were commonly owned at the time the invention in this application was made will preclude a rejection under 35 U.S.C. § 103 based upon the commonly assigned case as a reference under 35 U.S.C. § 102(f) or (g).

12. No claim is allowed.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (703) 308-3997. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

*PHILLIP GAMBEL*

Phillip Gambel, PhD.  
Primary Examiner  
Technology Center 1600  
March 12, 2001